Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539575 · ClinicalTrials.gov registry record · NA
CB1R in Synthetic Psychoactive Cannabinoids
A NA study of Drug Dependence, sponsored by Yale University.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03539575 is a NA study of Drug Dependence that is active but no longer recruiting, run by Yale University. The registered enrollment target is 15 participants, below the 304-participant average among 9 other Drug Dependence trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03539575, a NA study of Drug Dependence, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.
Conditions Studied
Interventions
- OTHER [11-C]OMAR
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539575
The ClinicalTrials.gov registry entry for NCT03539575 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 9 other Drug Dependence trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Dependence appearing as the primary indexed condition, and to 1 intervention - of which [11-C]OMAR is the first listed.
NCT03539575 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03539575 about?
NCT03539575 is a clinical study titled "CB1R in Synthetic Psychoactive Cannabinoids". The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.
What is the current status of trial NCT03539575?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2018-05-01. Estimated completion is 2025-12.
What conditions does trial NCT03539575 study?
This clinical trial studies the following conditions: Drug Dependence.
What interventions are being tested in trial NCT03539575?
The interventions under investigation include: [11-C]OMAR (OTHER).
Who is sponsoring clinical trial NCT03539575?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539575 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders
COMPLETED · NA
-
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
COMPLETED · NA
-
Innovative Digital Therapeutic for Smoking Cessation
COMPLETED · NA
-
Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use
COMPLETED · Phase 3
-
Drug Discrimination in Methadone-Maintained Humans Study 3
COMPLETED · Phase 1
-
The Effect of Fetal Gender on Maternal Substance Abuse Treatment
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.